Protalix BioTherapeutics (PLX) Stock Chart & Stock Price History $2.59 +0.05 (+1.97%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$2.54 -0.04 (-1.74%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock Protalix BioTherapeutics Stock Price Performance 5 Day Performance+0.39%1 Month Performance+12.12%3 Month Performance+22.17%6 Month Performance+156.44%Year-To-Date Performance+37.77%1 Year Performance+108.87% Receive PLX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PLX Stock Chart for Thursday, April, 3, 2025 PLX Chart by TradingViewRemove Ads Protalix BioTherapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization04/02/2025$2.54$2.59+1.97%$2.61$2.54385,876 shs$202.11 million04/01/2025$2.56$2.54-0.78%$2.59$2.50458,497 shs$198.20 million03/31/2025$2.58$2.56-0.78%$2.59$2.43547,904 shs$199.76 million03/28/2025$2.58$2.58$2.62$2.53465,209 shs$201.33 million03/27/2025$2.48$2.58+4.03%$2.60$2.46664,913 shs$201.33 million03/26/2025$2.53$2.48-1.98%$2.53$2.46324,030 shs$193.52 million03/25/2025$2.60$2.53-2.69%$2.61$2.52506,212 shs$197.42 million03/24/2025$2.49$2.60+4.42%$2.66$2.53999,675 shs$202.89 million03/21/2025$2.36$2.49+5.51%$2.49$2.30678,007 shs$194.30 million03/20/2025$2.25$2.36+4.89%$2.40$2.24555,831 shs$173.78 million Get the Latest News and Ratings for PLX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. 03/19/2025$2.35$2.25-4.26%$2.44$2.25701,436 shs$165.68 million03/18/2025$2.45$2.35-4.08%$2.51$2.221.20 million shs$173.04 million03/17/2025$2.24$2.45+9.38%$2.65$2.371.95 million shs$180.40 million03/14/2025$2.17$2.24+3.23%$2.24$2.16696,153 shs$164.94 million03/13/2025$2.24$2.17-3.13%$2.27$2.13594,162 shs$159.79 million03/12/2025$2.26$2.24-0.88%$2.30$2.22447,749 shs$164.94 million03/11/2025$2.33$2.26-3.00%$2.36$2.21557,984 shs$166.41 million03/10/2025$2.34$2.33-0.43%$2.36$2.302.35 million shs$171.57 million03/07/2025$2.37$2.34-1.27%$2.37$2.32467,852 shs$172.30 million03/06/2025$2.37$2.37$2.37$2.32616,665 shs$174.51 million03/05/2025$2.32$2.37+2.16%$2.37$2.32454,410 shs$174.51 million03/04/2025$2.31$2.32+0.43%$2.36$2.28591,536 shs$170.83 million03/03/2025$2.33$2.31-0.86%$2.41$2.30967,501 shs$170.10 million Related Companies Chimerix Stock Price Chart Evolus Stock Price Chart Praxis Precision Medicines Stock Price Chart Avadel Pharmaceuticals Stock Price Chart Replimune Group Stock Price Chart Xencor Stock Price Chart Intellia Therapeutics Stock Price Chart Anavex Life Sciences Stock Price Chart Gyre Therapeutics Stock Price Chart Rocket Pharmaceuticals Stock Price Chart Receive PLX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NYSE:PLX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
